Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 337.93%.

  • Autolus Therapeutics' EBIT Margin changed N/A to 337.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 535.8%, marking a year-over-year increase of 16308700.0%. This contributed to the annual value of 2385.63% for FY2024, which is 81974700.0% up from last year.
  • As of Q3 2025, Autolus Therapeutics' EBIT Margin stood at 337.93%.
  • In the past 5 years, Autolus Therapeutics' EBIT Margin registered a high of 0.02% during Q3 2021, and its lowest value of 261600.0% during Q4 2024.
  • Over the past 5 years, Autolus Therapeutics' median EBIT Margin value was 1151.41% (recorded in 2025), while the average stood at 26287.86%.
  • The largest annual percentage gain for Autolus Therapeutics' EBIT Margin in the last 5 years was 187687600bps (2023), contrasted with its biggest fall of -89912500bps (2023).
  • Autolus Therapeutics' EBIT Margin (Quarter) stood at 0.02% in 2021, then tumbled by -1861894bps to 318.39% in 2022, then tumbled by -3219bps to 10567.73% in 2023, then plummeted by -2375bps to 261600.0% in 2024, then surged by 100bps to 337.93% in 2025.
  • Its EBIT Margin was 337.93% in Q3 2025, compared to 292.58% in Q2 2025 and 726.34% in Q1 2025.